Newcells Biotech launches Lung Ciliary Beat Frequency Analysis assay

Newcells Biotech has launched its proprietary CiliaBeat software and its Lung Ciliary Beat Frequency Analysis assay. The cutting-edge software enables researchers to assess the effect of drugs and chemicals on the function of the ciliated cells within the lung small airways.

The technology has been extensively validated using Newcells’ physiologically relevant and established small airway epithelial cell (SAEC) model, demonstrating high sensitivity and predictiveness for safety and efficacy in pre-clinical drug development.

Newcells’ Lung Ciliary Beat Frequency Analysis assay generates reliable and predictive in vitro data on the activity of the beating cilia within the airways. It allows the assessment of dosing on mucus clearance, cilia function and evaluation of drug efficacy in reversing disease-like conditions. These parameters are particularly important to inform discovery and development for new drugs targeting lung conditions such as chronic obstructive pulmonary disorder (COPD), bronchiectasis, as well as the impact of airborne chemicals.

Developed to address a market gap for a software with high sensitivity, stability and speed, CiliaBeat complements the company’s recently launched high-content and high-throughput imaging suite, further strengthening Newcells’ position to provide market-leading imaging capabilities and meet growing customer demand for more data-rich and predictive preclinical studies.

The robust software is capable of rapid and unbiased analysis, maximising video inputs of beating ciliated cells whilst also minimising background noise. The high-definition videos are captured using an optimised set-up for increased sensitivity, generating accurate and in-depth datasets to accelerate programmes and inform lead compound selection, including for fast-acting drugs.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>